About Neuraceq®

High quality scans lead to better patient management decisions

Neuraceq® assists in the diagnostic assessment of cognitive impairment – helping you plan the clinical path ahead

  • Scientifically proven ability to detect the presence or absence of β-amyloid neuritic plaques, as demonstrated in a robust clinical trial program
  • High sensitivity and specificity
  • Reproducibility and reliability of visual assessment
  • A demonstrated safety profile with a low radiation dose
  • A wide, stable, and flexible scanning window

Diagnostic performance of Neuraceq® PET was thoroughly validated in a histopathology study, used in the real-world IDEAS study and in AD drug development studies

  • High sensitivity and specificity1
  • Approximately 30% of scans in IDEAS were performed with Neuraceq®2
  • Neuraceq® was involved in major AD drug development studies and used for confirming eligibility criteria and for therapy monitoring3

Reliability and reproducibility of the clinically applicable image interpretation methodology was confirmed1

This was validated in a study with 5 newly trained readers by way of electronic media training; 461 images from previous clinical studies were included from subjects with a range of diagnoses.

  • Inter-reader agreement across all 5 readers had a kappa coefficient of 0.79 (95% CI 0.77, 0.83)

  • Inter-reader reproducibility assessed from 46 images (10% of overall sample) ranged from 91% to 98%

PET reading results from IDEAS investigators confirmed by expert readers

Average interrater agreement between individual experts and local readers was highest for Neuraceq® among all three amyloid PET tracers used in IDEAS study4

1. Neuraceq® prescribing information. Life Molecular Imaging; 2024

2. La Joie et al. AAIC 2023

3. van Dyck et al. 2022, Sims et al. 2023, Bateman et al. 2023

4. Windon C. et al. HAI 2024

Neuraceq® has an established safety profile and a low radiation dose

The safety of Neuraceq® was evaluated in 872 subjects from 9 clinical trials

There were no reported serious adverse reactions (ARs) in these trials

All reported ARs were mild to moderate and of short duration

The most common ARs were erythema (1.7%), irritation (1.1%), and pain (3.4%) at the injection site

Neuraceq® delivers a lower radiation dose than a typical chest CT scan.